ResMed Inc. filings document operating results, governance actions, capital returns and securities registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and fiscal-year financial results, record board-declared cash dividends and describe the treatment of NYSE common stock and ASX CHESS Depositary Interests in dividend payments.
The company’s regulatory record also covers board composition, director elections, executive officer transitions, compensation arrangements and amendments to the ResMed Inc. 2009 Incentive Award Plan. Proxy materials provide stockholder voting matters, executive compensation disclosure and corporate-governance information for the medical technology company’s public-company structure.
ResMed Chairman and CEO Michael J. Farrell exercised options for 4,991 common shares on October 7, 2026, at an exercise price of $146.34 per share, then sold 4,991 shares at a weighted average price of $226.3349 per share.
The reported transactions were conducted under a Rule 10b5-1 plan adopted October 31, 2024. Following the exercise, the reported option balance was 4,993 options; an indirect holding of 2,090 common shares was reported through the Lisette and Michael Farrell Family Trust.
ResMed Inc. is named as issuer in a notice reporting Michael Farrell’s proposed sale of 4,991 common shares, with an aggregate market value of $1,129,637.70. The sale is listed through Fidelity Brokerage Services LLC for approximately October 7, 2026, on NYSE. A separate securities detail lists a cash-paid stock option exercise of 4,991 shares on October 7, 2026. The past-three-months table lists three earlier sales of 4,991 shares each.
ResMed Inc. (RMD) is asking stockholders to elect 10 directors, ratify PricewaterhouseCoopers LLP (PwC) as its fiscal 2027 auditor, and approve named executive officer compensation on an advisory basis. The board recommends votes FOR all three proposals. Fiscal 2026 revenue grew 8% in constant currency, non-GAAP diluted earnings per share grew 17%, and free cash flow exceeded $1.6 billion.
ResMed completed its acquisition of Noctrix Health for a gross purchase price of $340 million and closed the MatrixCare divestiture on September 1, 2026. For fiscal 2027, it expects to repurchase approximately $1.5 billion of shares, inclusive of an accelerated share repurchase, and plans more than $1.85 billion in total stockholder returns, including a 10% increase in the quarterly dividend to $0.66 per share.
Carol Burt is to become lead director on November 15, 2026, succeeding lead director Ron Taylor, who is not standing for reelection and will retire after the November 18, 2026 annual meeting; the board will then have 10 directors. ResMed appointed PwC beginning with the review of fiscal 2027 first-quarter financial statements, replacing KPMG, which audited fiscal 2026. Aaron Bloomer succeeded Brett Sandercock as chief financial officer.
ResMed Inc. (RMD) amended the ownership report for Michael J. Farrell, Chairman and CEO, to update his reported share position following a previously reported transaction. As of September 8, 2026, the report lists 479,803 shares held directly and 2,090 shares held indirectly through the Lisette and Michael Farrell Family Trust.
Justin Leong, ResMed Inc.’s Chief Product Officer, acquired 6,461 shares of ResMed common stock on August 14, 2026, associated with performance-based restricted stock units. The compensation and leadership development committee certified that the applicable performance metrics were met. His reported direct holdings after the transaction were 35,489 shares.
ResMed Inc. reports that Global General Counsel Michael J. Rider acquired 3,230 shares in an award of performance-based restricted stock units earned on August 14, 2026. The units were granted on November 20, 2025, and vest one-third each year on the grant anniversary. Rider’s direct common-stock holdings following the transaction were 12,718 shares.
ResMed Inc. Chairman and CEO Michael J. Farrell reported an award-related acquisition of 13,547 common shares tied to performance-based restricted stock units. The units were granted November 20, 2025, and the shares were earned August 14, 2026, when the compensation committee certified that the performance metrics were met. The units vest one-third each year on the grant anniversary. Farrell's reported direct holdings after the transaction were 479,803 shares; a separate indirect holding lists 2,090 shares in the Lisette and Michael Farrell Family Trust.
ResMed Inc. Chief Financial Officer Aaron Bloomer reported acquiring 9,072 shares of common stock on August 14, 2026, representing performance-based restricted stock units granted June 1, 2026. The units were earned when the compensation and leadership development committee certified that the applicable performance metrics were met. Bloomer reported direct holdings of 9,072 shares following the transaction.
RESMED INC (RMD) reported that Chairman and CEO Michael J. Farrell exercised stock options for 4,991 shares of ResMed common stock on September 8, 2026, at an exercise price of $146.34 per share and sold the same 4,991 shares at a weighted average price of $222.44 per share. The transactions were conducted under a Rule 10b5-1 trading plan adopted October 31, 2024. After the option exercise, Farrell held 9,984 stock options directly and 2,090 shares indirectly through the Lisette and Michael Farrell Family Trust.